Stocklytics Platform
Asset logo for symbol QURE
uniQure NV
QURE61
$8.16arrow_drop_down3.65%-$0.31
Asset logo for symbol QURE
QURE61

$8.16

arrow_drop_down3.65%

Performance History

Chart placeholder
Key Stats
Open$9.14
Prev. Close$8.47
EPS-6.20
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range8.44
10.01
52 Week Range3.73
11.35
Ratios
EPS-6.20

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$850.34
Perf. (24h)
arrow_drop_down6.10%-$55.25
Market Cap$815.39B
Price$566.32
Perf. (24h)
arrow_drop_down1.21%-$6.95
Market Cap$464.20B
Price$156.42
Perf. (24h)
arrow_drop_down0.10%-$0.16
Market Cap$376.83B
Price$123.33
Perf. (24h)
arrow_drop_down2.02%-$2.55
Market Cap$318.85B

About uniQure NV (QURE)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Matthew Craig Kapusta
Headquarters
Amsterdam
Employees
501
Exchange
NASDAQ
add uniQure NV to watchlist

Keep an eye on uniQure NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is uniQure NV's (QURE) price per share?

The current price per share for uniQure NV (QURE) is $8.16. The stock has seen a price change of -$0.31 recently, indicating a -3.66% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for uniQure NV (QURE)?

For uniQure NV (QURE), the 52-week high is $11.35, which is 39.09% from the current price. The 52-week low is $3.73, the current price is 118.77% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is uniQure NV (QURE) a growth stock?

uniQure NV (QURE) has shown an average price growth of 0.41% over the past three years. It has received a score of 14 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying uniQure NV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is uniQure NV (QURE) stock price performance year to date (YTD)?

As of the latest data, uniQure NV (QURE) has a year-to-date price change of 17.75%. Over the past month, the stock has experienced a price change of 73.99%. Over the last three months, the change has been 74.73%. Over the past six months, the figure is 43.41%. Looking at a longer horizon, the five-year price change stands at -88.74%.

help
Is uniQure NV (QURE) a profitable company?

uniQure NV (QURE) has a net income of -$308.48M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 13.98% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -637.16% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $15.84M, although specific revenue growth data is currently not available. The gross profit is $2.22M. Operating income is noted at -$282.87M. Furthermore, the EBITDA is -$235.84M.

help
What is the market capitalization of uniQure NV (QURE)?

uniQure NV (QURE) has a market capitalization of $411.21M. The average daily trading volume is 15.57M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level